 Trial Status
February 26th, 2018
5954 participants are enrolled
59 participants enrolled last week!
324 participants are in screening
119 sites are open for enrollment
37 sites enrolled at least 1 participant in the past week
34 sites screened at least 1 participant in the past week

Since the last newsletter, 118 participants have been enrolled. **Thank you for the excellent effort that all teams are putting forth to enroll participants in REPRIEVE.**

Welcome!
We would like to extend a warm welcome to the newest site to open for enrollment in REPRIEVE! **Site 30313 Parirenyatwa, located in Harare, Zimbabwe.**

**Thank You to All Sites Enrolling Participants Week of February 19th, 2018!**

Duke University Medical Center
Case CRS
Northwestern University CRS
The Ponce de Leon Ctr. CRS
University of Colorado Hospital CRS
Penn Therapeutics CRS
Weill Cornell Uptown CRS
Family Clinical Research Unit
Wits Helen Joseph Hospital CRS (Wits HJH CRS)
Barranco CRS
San Miguel CRS
Chennai Antiviral Research and Treatment (CART) CRS
Hospital Nossa Senhora da Conceicao CRS
SOWETO
Joint Clinical Research Centre (JCRC)/Kampala CRS
Gaborone CRS
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Columbia Physicians and Surgeons CRS
Byramjee Jeejeebhoy Government Medical College (BJMC) CRS
Denver Public Health
GHESKIO Institute of Infectious Diseases and Reproductive Health
Chiang Mai University HIV Treatment CRS
Thai Red Cross AIDS Research Center
Los Angeles LGBT Center
Drexel University
Florida Department of Health Hillsborough County
UT Southwestern
James J Peters VA Medical Center
Mount Sinai Downtown CRS
Toronto General Hospital
Centro de Pesquisas Clinicas ICHCFMUSP CRS
HGNI HIV Family Care Clinic HHFCC
Tropical Medicine Foundation
University of Toledo Medical Center
Centro de Referencia e Treinamento
Inova Heart and Vascular Institute
Palmetto Health Clinical Trial Department
Full Speed to 1500 Challenge Updates!
Since the Full Speed to 1500 Challenge began on December 4th, 2017, 831 participants have been enrolled, we are over halfway to the goal of 1500 participants!

Don't forget prizes include:

- $500 gift card for 1st place
- $250 gift card for 2nd place
- All other sites that enroll 15 participants by May 1st will win a $100 gift card

Check out the standings below!
Entering Medications on the Medications Log (TXW0295)

Q. How should medications be recorded on the Medications Log?
A. Refer to the REPRIEVE (A5332) MOPS, section 5.0 for instructions about the time frames for all medication/treatment categories we wish to have entered. Medications need to be recorded as they are taken per pill. Do not record the full medication history for the participant on the Medications Log.

Q. What is considered the medication Start Date?
A. Provided the participant has been continuously taking the medication/treatment in the current formulation, the Start Date would be the date of the first dose. Likewise, the End Date should be the date of the last dose.

Q. In the case of a drug being taken initially in a combination, then later and currently
individually, what should be considered the Start Date of the drug?

A. If the drug is currently taken individually as a single pill, enter the Start Date when the first dose of the drug was initiated as a single pill and continue until the present (assuming there has been no extended interruption in use).

**Example Record 1:**

Participant reports ARV history below:

Estavudine, Lamivudine and Indinavir 5/15/1996 – 1/14/1998


Lamivudine, Tenofovir Dapiviril Fumarate, Efavirenz – 1/21/2000-7/14/2017

Lamivudine, Tenofovir Dapiviril Fumarate, Darunavir/r, Etravirine, Dolutegravir – 7/15/2017 – present

The following would be entered on the Medications Log:

<table>
<thead>
<tr>
<th>Category</th>
<th>Term</th>
<th>Prior?</th>
<th>Start Date:</th>
<th>End Date:</th>
<th>Ongoing?</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARV</td>
<td>Lamivudine</td>
<td>Y</td>
<td>21-Jan-00</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Tenofovir Dapiviril Fumarate</td>
<td>Y</td>
<td>21-Jan-00</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Etravirine</td>
<td>Y</td>
<td>15-Jul-17</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Dolutegravir</td>
<td>Y</td>
<td>15-Jul-17</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Darunavir/r</td>
<td>Y</td>
<td>15-Jul-17</td>
<td></td>
<td>Y</td>
</tr>
</tbody>
</table>

**Example Record 2:**

If the participant had held all ARVs for an extended period prior to the most recent regimen:

Lamivudine, Tenofovir Dapiviril Fumarate, Efavirenz 1/21/2000-5/10/2014

Lamivudine, Tenofovir Dapiviril Fumarate, Darunavir/r, Etravirine, Dolutegravir – 7/15/2014 – present

In this case, all drugs in the current regimen would have a start date of 7/15/2014

The following would be entered on the Medications Log:

<table>
<thead>
<tr>
<th>Category</th>
<th>Term</th>
<th>Prior?</th>
<th>Start Date:</th>
<th>End Date:</th>
<th>Ongoing?</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARV</td>
<td>Lamivudine</td>
<td>Y</td>
<td>15-Jul-14</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Tenofovir Dapiviril Fumarate</td>
<td>Y</td>
<td>15-Jul-14</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Etravirine</td>
<td>Y</td>
<td>15-Jul-14</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Dolutegravir</td>
<td>Y</td>
<td>15-Jul-14</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>ARV</td>
<td>Darunavir/r</td>
<td>Y</td>
<td>15-Jul-14</td>
<td></td>
<td>Y</td>
</tr>
</tbody>
</table>

If you have questions about this email the REPRIEVE Data Managers at reprieve.dmc@fstrf.org
Report Potential Adjudicated Events

One essential role we want to remind sites of periodically is to identify and report potential adjudicated events!

Adjudicated Events in REPRIEVE are:

- Atherosclerotic or other CVD death
- Nonfatal myocardial infarction
- Unstable angina hospitalization
- Coronary or peripheral arterial revascularization
- Peripheral arterial ischemia
- Nonfatal stroke or transient ischemic attack (TIA)
- Heart failure
- Death from any cause

Important steps in identifying and reporting adjudicated events include:

- Take a thorough history from the participant and review the medical record to identify any potential adjudicated events.
- Ensure that the Heart-related Health Questionnaire has been completed and is kept with source documents.
- Ensure that 100% of Adjudicated Event Tracking CRFs have been completed accurately and necessary steps have been taken to submit any potential events for adjudication as per section 6.0 of the REPRIEVE (A5332) MOPS.

If your site does submit a packet for a potential adjudicated event, please make sure that the Site PI or their designee reviews the packet and agrees with the content before it is submitted to the REPRIEVE Data Coordinating Center.

Mechanistic Substudy (A5333s): Critical Need to Complete Month 24 CCTA!

- Please be aware of upcoming Month 24 CCTAs!
  - Every participant in A5333s must have their month 24/follow-up coronary CT angiogram (CCTA). If the month 24 CCTA will be out of the window, please email the A5333s team at actg.corea5333s@fstrf.org for guidance on how to proceed.
  - Please contact participants to remind them of their required month 24 CCTA and schedule CCTA appointments as soon as possible.
  - Retention/Scheduling Strategy:
Schedule a participant’s CCTA with concurrent scheduled appointments the participant might have already scheduled. One easy way to accomplish this is by checking participant’s EMR (i.e on Epic) for other upcoming appointments.

*It is important to obtain the Month 24 follow-up CCTA. We CANNOT assess the primary outcome of A5333s, change in coronary plaque unless the participant has both the entry and month 24 CCTA.*

Please contact Devvora Olalere (DOLALERE@mgh.harvard.edu) if you have any questions or concerns.

---

**Did You Miss the Monthly Site Call?**

In case you missed it, you can review the monthly site call slides here.

Topics covered include:

- Retention
  - American Heart Month, with special presentation by the Puerto Rico Site
  - LOA Submission/Updated ACTG LPC
  - LDMS Preloads and Quick Add
  - Medications Log
  - Mechanistic Substudy Updates

---

As Heart Month comes to a close, we would like to share some photos from REPRIEVE teams across the US who promoted heart health awareness and the REPRIEVE trial this month. Sites were overwhelmingly positive about their participation in this effort.
“The REPRIEVE campaign has given us an extra push to do some outreach we may not have done without the campaign.” - Bob Bucklew, Outreach Coordinator, Site 2501, Case CRS.

The UT Southwestern REPRIEVE Team in their Go Red For Women Day attire for Heart Month

Case CRS’s Heart Health Awareness table in the John T. Carey Special Immunology Unit waiting
The Puerto Rico AIDS CRS REPRIEVE Team hosted a Heart Health Awareness event and table at their clinic in San Juan.

Thank you to all sites that hosted Heart Health Awareness tables and events!

New My Heart Matters Blog by Follow YOUR Heart

The Follow YOUR Heart Campaign invites you to read the newest My Heart Matters blog post, Women Supporting Women in the Community. This blog addresses why HIV community organizations are beneficial to women and how women can find HIV community organizations near them. This is helpful for providers and a great resource to share with participants!
The My Heart Matters blog is a great resource to help facilitate communication between REPRIEVE investigators and women with HIV who are interested in learning more about heart health, research participation, and the REPRIEVE trial. Please share this webpage with your participants. The blog is updated every other month.

**REPRIEVE In the News**

NIAID (National Institute of Allergy & Infectious Disease) featured REPRIEVE on their blog! The post features a summary of REPRIEVE and its importance for those living with HIV, just in time for Heart Health Awareness Month. Read the article here.

**Happy Heart Month: What People Living with HIV Should Know**

Today marks not just a time to exchange valentines and chocolates, but also the midpoint of American Heart Month. Did you know people living with HIV are at an increased risk of experiencing cardiovascular disease? Fortunately, NIH-supported research is getting to the heart of the problem.

Effective anti-HIV medications dramatically reduced the number of AIDS-related deaths in the United States. However, because people with HIV are now able to live longer than before, cardiovascular disease has emerged as a leading cause of death.

**REPRIEVE (A5332): Are you up to date?**

For A5332 please use

- **Current Protocol Documents:**
  - Protocol Version 3.0 dated 01/28/2016
  - Clarification Memo #1 dated 04/04/2016
  - Clarification Memo #2 dated 04/12/2016 (corrects an error in CM #1)
  - Clarification Memo #3 dated 12/27/2016
  - Letter of Amendment, Version 3.0 #1 dated 08/17/16
  - Letter of Amendment, Version 3.0 #2, dated 04/14/17
  - Letter of Amendment, Version 3.0 #3, dated 01/19/2018

- **MOPS Version 3.0:** dated 09/20/2017

- **A5332 LPC for ACTG Sites:** Version 3.0 dated 02/02/2018

- **A5332 LPC for Non-ACTG Sites:** Version 3.0 dated 09/21/2017

These documents are on the A5332 PSWP.
Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use

**Protocol:** Version 3.0 dated 01/28/2016
**MOPS:** Version 3.0 dated 06/05/2017
**A5333s LPC:** Version 3.0, dated 09/21/2017

These documents are on the [A5333s PSWP](#).

For future reference, all newsletters are available on the [REPRIEVE Website](#).

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at [reprieve.news@fstrf.org](mailto:reprieve.news@fstrf.org).

---

REPRIEVE Trial Clinical Coordinating Center
Massachusetts General Hospital
55 Fruit Street, 5LON 207
Boston, MA USA 02144

Our mailing address is:
reprieve.news@fstrf.org

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

---

This email was sent to <<Email Address>>

why did I get this?  unsubscribe from this list  update subscription preferences

Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA